Differential Impact of Interferon-Based and Direct-Acting Antiviral Therapies on Bone Metabolism in Chronic Hepatitis C: Insights from Transcriptomic and Clinical Analyses
Calcified Tissue International · 2025
DOI: 10.1007/s00223-025-01435-0 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Calcified Tissue International, 2025. Verfasst von Yi-Lin Chiu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department and Graduate Institute of Biochemistry, College of Biomedical Sciences, National Defense Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Chronic, Interferons, Bone and Bones. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Tri-Service General Hospital, Medical Affairs Bureau, Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
Chronic hepatitis C (CHC) is a risk factor for hepatic osteodystrophy, increasing osteoporosis and fracture risks. While historical pegylated interferon/ribavirin (PEG-IFN/RBV) showed variable bone effects, the newer direct-acting antivirals' (DAAs) impact is less clear. This study compared these antiviral strategies' effects on bone metabolism in CHC patients through two separate analyses. First, we conducted a retrospective analysis of a prospectively collected observational cohort (n = 73) to assess longitudinal bone mineral density (BMD) and bone turnover marker (BTM) changes following PEG-IFN/RBV or DAA therapies. Second, to explore mechanisms, we analyzed two independent, publicly available peripheral blood mononuclear cell (PBMC) transcriptomic cohorts from CHC patients treated with PEG-IFN/RBV (GSE7123, n = 69) or an IFN-free DAA regimen (GSE51699, n = 8). Clinically, PEG-IFN/RBV induced a temporary lumbar spine BMD increase, then a post-treatment decline, and modulated BTMs. DAAs showed minimal BMD/BTM effects. PBMC transcriptomics revealed PEG-IFN/RBV responders showed downregulation of osteoclast precursor (OCP)-related gene sets and concurrent upregulation of osteoblast-related gene sets. DAAs had a minimal impact on these PBMC pathways. These findings demonstrate distinct effects of PEG-IFN/RBV and DAA therapies. PEG-IFN/RBV significantly modulates PBMC gene expression related to bone remodeling, potentially contributing to the complex clinical BMD changes, while DAAs appear largely bone-neutral. This highlights treatment-specific osteoporosis risk and surveillance needs in CHC survivors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department and Graduate Institute of Biochemistry, College of Biomedical Sciences, National Defense Medical University, Taipei, Taiwan.
- Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
- Institute of Preventive Medicine, National Defense Medical University, Taipei, Taiwan.
- Division of Gastroenterology, Department of Internal Medicine, Taichung Armed Forces General Hospital, Taichung, Taiwan.
- Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
ORCID-Profile: Jung-Chun Lin
Förderung
- Tri-Service General Hospital
- Medical Affairs Bureau
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Chiu, Y. L., Hsieh, T. Y., Hsu, Y. J., Huang, T. Y., Liao, C. H., Lu, M. C., Liu, F. C., Chou, Y. T., Chang, C. F., Huang, I. H., Chen, B. C., Lin, H. H., Shih, Y. L., Yang, Y. J., & Lin, J. C. (2025). Differential Impact of Interferon-Based and Direct-Acting Antiviral Therapies on Bone Metabolism in Chronic Hepatitis C: Insights from Transcriptomic and Clinical Analyses. Calcified Tissue International. https://doi.org/10.1007/s00223-025-01435-0
Vancouver
Chiu YL, Hsieh TY, Hsu YJ, Huang TY, Liao CH, Lu MC, et al. Differential Impact of Interferon-Based and Direct-Acting Antiviral Therapies on Bone Metabolism in Chronic Hepatitis C: Insights from Transcriptomic and Clinical Analyses. Calcified Tissue International. 2025. doi:10.1007/s00223-025-01435-0
BibTeX
@article{Chiu2025,
author = {Chiu, Yi-Lin and Hsieh, Tsai-Yuan and Hsu, Yu-Juei and Huang, Tien-Yu and Liao, Chang-Hung and Lu, Meng-Chuan and Liu, Fang-Chen and Chou, Yi-Ting and Chang, Chao-Feng and Huang, I-Hsuan and Chen, Bao-Chung and Lin, Hsuan-Hwai and Shih, Yu-Lueng and Yang, Yun-Ju and Lin, Jung-Chun},
title = {Differential Impact of Interferon-Based and Direct-Acting Antiviral Therapies on Bone Metabolism in Chronic Hepatitis C: Insights from Transcriptomic and Clinical Analyses},
journal = {Calcified Tissue International},
year = {2025},
doi = {10.1007/s00223-025-01435-0}
}
EUVIMED